USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS
Liang Deng,Stewart Shuman,Jedd D. Wolchok,Taha Merghoub,Peihong Dai,Weiyi Wang
申请号：
US15553222
公开号：
US20180236062A1
申请日:
2016.02.25
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
